WASHINGTON -- An investigational dual therapy appeared to show antiviral activity in patients with chronic hepatitis D virus (HDV) infection, according to the phase II SOLSTICE trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback